Different outcomes of cardiologic safety of trastuzumab in adjuvant or metastatic setting in patients with breast cancer: A single institution experience.

e11028 Background: Trastuzumab is a monoclonal antibody developed to target HER 2 receptor inhibit tumour cells proliferation that overexpress HER 2.Trastuzumab is active and is viable in breast cancer in neoadjuvant, adjuvant or metastatic setting. The most serious adverse event of trastuzumab is cardiotoxicity. We evaluate different cardiologic toxicity in patients with breast cancer treated with trastuzumab in metastatic or adiuvant setting. Methods: Jan 2006 - Dec 2010 were treated, 84 patients with metastatic breast cancer (MBC). While Aug 2006 - Dec 2010 were admitted 140 patients affected by breast cancer treated in adjuvant setting of whom 110 able to be assessed. MBC sample: 84 patients (2M/82 F) median age 54 (range 27-86 yy). 77 patients underwent surgery for primary tumor. 70 have received also complementary radiotherapy and 62 patients have received adjuvant chemotherapy with antracyclines and 14 chemotherapy without antracyclines. In the metastatic setting patients have started trastuzumab f...